Intelligence · Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring ≤24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.
-
US 6825186
Method and compositions for treating atheroma, tumors and other neoplastic tissue
expired -
US 6825326
PSCA: prostate stem cell antigen and uses thereof
expired -
US 6821517
Compositions and methods for enhancing immune responses mediated by antigen-presenting cells
expired -
US 6821505
Immunoglobin-like domains with increased half lives
expired -
US 6821742
Conformational and topological protein regulation
expired -
US 6821750
ABCG8 vectors, host cells, and method of making
expired -
US 6822071
Polypeptides from Chlamydia pneumoniae and their use in the diagnosis, prevention and treatment of disease
expired -
US 6821739
Methods of diagnosing and treating Crohn's disease using Pseudomonas antigens
expired -
US 6821522
Tumor Therapy
expired -
US 6818213
Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
expired -
US 6818202
Enhancement of NMR and MRI in the presence of hyperpolarized noble gases
expired -
US 6818620
Synthetic compounds and compositions with enhanced cell binding
expired -
US 6818223
Abundant extracellular products and methods for their production and use
expired -
US 6820011
Three-dimensional structure of complement receptor type 2 and uses thereof
expired -
US 6818016
Methods for coating stents with DNA and expression of recombinant genes from DNA coated stents in vivo
expired -
US 6814980
Microspheres containing condensed polyanionic bioactive agents and methods for their production
expired -
US 6815431
Methods for therapy of neurodegenerative disease of the brain
expired -
US 6815416
Stimulation of cartilage growth with agonists of the non-proteolytically activated thrombin receptor
expired -
US 6815574
Methods of simulating human prostate cancer progression
expired -
US 6814970
Methods and compositions including a 13 kD B. burgdorferi protein
expired -
US 6811787
Over-expressing homologous antigen vaccine and a method of making the same
expired -
US 6811776
Process for ex vivo formation of mammalian bone and uses thereof
expired -
US 6812336
Transcription factor coactivator protein, p/CIP
expired -
US 6812034
Fetuin-MGP-mineral complex in serum assayed to determine calcification risk
expired -
US 6808880
Method for detecting polynucleotides encoding telomerase
expired -
US 6808878
Genes from the 20Q13 amplicon and their uses
expired -
US 6808702
Treatment of disorders by implanting stem cells and/or progeny thereof into gastrointestinal organs
expired -
US 6808875
Methods for screening cellular proliferation using isotope labels
expired -
US 6806084
Methods for compositions for in vivo gene delivery
expired -
US 6806065
Rickettsia felis outer membrane protein
expired -
US 6806354
Methods and compositions for inducing autoimmunity in the treatment of cancers
expired -
US 6805858
Methods for the administration of adenovirus p53
expired -
US 6806080
Hybrid vectors for gene therapy
expired -
US 6806363
Cobalamin conjugates useful as antitumor agents
expired -
US 6803371
Purine inhibitors of protein kinases, G proteins and polymerases
expired -
US 6803053
Lipidic microparticles linked to multiple proteins
expired -
US 6803359
Inhibition of abnormal cell growth with corticotropin-releasing hormone analogs
expired -
US 6803375
Non-peptide inhibition of T-lymphocyte activation and therapies related thereto
expired -
US 6800745
Indolicidin analogs and methods of using same
expired -
US 6800286
Chimeric fibroblast growth factor proteins, nucleic acid molecules, and uses thereof
expired -
US 6800615
Antihelminthic anthraquinones and method of use thereof
expired -
US 6797721
Phorboxazole derivatives for treating cancer
expired -
US 6797495
Somatic cells with ablated PrP gene and methods of use
expired -
US 6797702
Methods and compositions comprising DNA damaging agents and P53
expired -
US 6797738
Open pore biodegradable matrices
expired -
US 6794150
Assay for YKL-40 as a marker for degradation of mammalian connective tissue matrices
expired -
US 6794128
Methods of selecting internalizing antibodies
expired -
US 6790939
Anti-PSCA antibodies
expired
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources · Patent directory